Allogene blueprints a new manufacturing complex for next-gen CAR-T; Inovio spins out neoantigen upstart with $10.5M A round
→ David Chang and Arie Belldegrun are back in the business of building manufacturing facilities. Their startup Allogene $ALLO has inked a deal to build a state-of-the-art cell therapy manufacturing site in Newark, CA. That may sound a bit mundane in the world of drug development, but it’s critical to the company’s longterm success — as the two founders learned starting Kite.
One of the best funded biotech startups in the class of 2018, Allogene is adding a 118,000-square-foot facility at the Gateway 84 Silicon Valley advanced manufacturing campus. The company also plans to continue using a CMO for added production of their off-the-shelf CAR-Ts, which they believe is on track to supplant the two pioneering personalized CAR-Ts on the market.
→ Inovio is spinning out a startup biotech that will jump into the neoantigen field. Geneos Therapeutics will start out with platform tech from Inovio and $10.5 million in launch money from a Series A round led by Santé Ventures. The biotech is based in Plymouth Meeting, PA.
→ Novo Nordisk and Abbott are integrating their products to give diabetics a better view of their insulin and glucose data together as they manage their disease. These new digital initiatives are all the rage these days.
→ Ultragenyx $RARE says it has rounded up encouraging data from the first cohort of their Phase I/II study of DTX401, an AAV-based gene therapy for the treatment of glycogen storage disease type Ia.
→ Amgen, Cytokinetics and Servier have launched their second Phase III study of omecamtiv for heart failure patients.